News

Call for Abstracts to Present at MHSRS 2021

The call for abstracts to present a poster at this year’s Military Health System Research Symposium (MHSRS) is now open through March 31. They are planning for this year’s conference to be in person. The dates are pending, but usually are in mid- to late-August in Orlando, FL. G2G account managers will reach out separately and in your next check-in call re: assisting with a submission. Details below.

NOTE: DoD-sponsored SARS CoV-2 (COVID-19) related research will be highlighted in dedicated 2021 MHSRS breakout sessions. Oral presentations at these sessions will be by invitation only.

* The Call for Abstracts will be for posters only. COVID-19 related research abstracts submitted to sessions other that those that are focused on COVID-19 will be re-directed to the COVID-19 session leads for poster consideration.

* For 2021, a special MHSRS award category for COVID-19 research will be offered for individuals and teams.

2021 MHSRS Call for Abstracts
February 17, 2021 to March 31, 2021
The deadline will not be extended past 31 March 2021.

How to Submit a 2021 Abstract
(1) Complete the abstract submission form, (2) upload a CV, (3) upload a signed Conflict of Interest (COI) form

The abstract should be no more than 8000 characters in length. There are no format or font restrictions. No embedded tables, pictures, or videos will be accepted. Have the presenter CV and signed COI form in pdf format ready to upload when you initiate abstract submission to facilitate the submission process.

Link to submit and Abstract: https://mhsrs.amedd.army.mil/SitePages/Submit-an-Abstract.aspx

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation